INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary Dr. Patrick Soon-Shiong Presents at the 36th Annual J.P. Morgan Healthcare Conference
Download Presentation (PDF) To watch the Webcast To Listen to the Webcast
View HTML
Toggle Summary DR. PATRICK SOON-SHIONG TO GIVE KEYNOTE ADDRESS AND NANTKWEST TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH 2016 HEALTH CARE CONFERENCE
Culver City, May 6, 2016 -- NantKwest, Inc (Nasdaq:NK), today announced that Dr. Patrick Soon-Shiong, NantKwest's Chairman and CEO will be giving the Keynote address and NantKwest will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday,
View HTML
Toggle Summary Engineered Killer Immune Cells Target Tumours and Their Immunosuppressive Allies View HTML
Toggle Summary FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity
First human adenovirus (hAd5) vector vaccine candidate to deliver both outer spike (S) and inner nucleocapsid (N) antigens from SARS-CoV-2, offering potential long-term T cell and antibody immunity to the SARS-CoV-2 virus Second-generation adenoviral vector platform designed to generate immune
View HTML
Toggle Summary ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for potential long-lasting humoral and
View HTML
Toggle Summary ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious disease programs for HIV and COVID-19
View HTML
Toggle Summary ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- ImmunityBio, a privately-held immunotherapy company, today announced the publication in
View HTML
Toggle Summary ImmunityBio Appoints Fabio M. Benedetti, M.D. as Chief Strategy Officer
Dr. Benedetti Brings More Than 20 Years in Oncology Clinical Development and Global Large Pharma Experience  CULVER CITY, Calif., December 30, 2020 –  ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti, M.D.
View HTML
Toggle Summary ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics
Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves Computer-based molecular dynamics
View HTML
Toggle Summary ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory.  Inclusion of nucleocapsid in this vaccine construct potentially
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.